

# ABOUT THE AUTHOR

Carolyn Jack, MDCM, PhD, FRCPC

Dr. Carolyn Jack is an Assistant Professor at McGill University, and an Investigator at the Infectious Diseases and Immunity in Global Health Program of the Research Institute of the McGill University Health Centre. In 2018, Dr. Jack founded the McGill University Hospital Network Center of Excellence for Atopic Dermatitis, the first tertiary care centre in Canada dedicated to adult atopic dermatitis. She is the co-founder of EczemaQ, an award-winning mobile health application, and the registered non-profit Patient Advisory Committee known as Eczéma Québec. As a clinician scientist, her research goal is to identify disease-modifying interventions in chronic atopic dermatitis.





# SYSTEMIC MANAGEMENT OF ATOPIC DERMATITIS: NEW AND EMERGING THERAPIES

## 1. ATOPIC DERMATITIS

Atopic dermatitis, also known as atopic eczema (hereafter referred to as eczema) is the most common chronic inflammatory skin disease worldwide and, together with associated allergies, asthma, allergic rhinitis (with or without nasal polypsis), and eosinophilic esophagitis, atopic disorders represent a growing source of patient morbidity and health care cost globally.<sup>1,2</sup> The incidence of eczema spans all age groups, but in over 80% of cases it manifests during infancy or early childhood; interestingly, there is now recognition that a significant number of patients suffer from adult-onset, chronic-persistent, and/or late-relapsing disease.<sup>1,3,4</sup> Eczema is a complex disease with extreme heterogeneity, including highly variable penetrance, clinical phenotypic presentations (ethnicity, age and temporal factors), and natural history across the lifespan. The term endotype has been introduced to describe potential variance in therapeutic responsiveness and etiology, particularly with respect to genetic and immunologic profiling, as well as environmental triggering.<sup>1,4-6</sup> Notably, the range of treatment options available for patients with atopic disorders is changing rapidly, especially for eczema.<sup>7</sup> In this review, we provide a brief overview of targeted systemic therapeutic options for patients with eczema and atopy (**Table 1**).

## 2. WHO QUALIFIES FOR SYSTEMIC THERAPY?

A detailed approach to the management of eczema is beyond the scope of this review; however, our group has published a systematic review and quality assessment of existing guidelines for reference.<sup>8</sup> Management options range from skin-directed (topical corticosteroids, calcineurin inhibitors, PDE4 inhibitors, as well as phototherapy) to systemic agents, based on extent, severity, and type of disease.<sup>1,5,8</sup> Notably, assessment of disease is challenging, as highly-detailed full body skin examinations are required for validated disease assessment, including the primary outcome measure, the Eczema Area and Severity Index (EASI).<sup>9</sup> A stepwise approach to management of refractory or more severe disease generally focuses on systemic agents to induce itch remission rapidly, a core factor to drive improvement in quality of life. Objectively,

a current target for eczema control is an EASI of <7; however, patient reported outcomes for itch and quality of life, such as the Dermatology Life Quality Index (DLQI), should strongly influence this target.<sup>1,8,9,53</sup> The importance of these subjective measures is highlighted when considering the temporal instability of the disease and the barriers to accessing specialized care and objective measures during flares. For individuals with refractory or extensive eczema affecting more than ten percent corporeal surface area, or special sites such as the hands or face, antimetabolite immunosuppressive agents have long been used, despite being off-label.<sup>1,5,8,10,11</sup> Therapeutic switches for ensuring safety of continuous immunomodulation for long-term maintenance of remission are now preferred management, as targeted therapies are considered to minimize the risk of adverse effects across the lifespan.<sup>1,5,8,11</sup> Patients and providers alike are increasingly seeking direct access to targeted agents when able. Broadly, targeted agents approved for eczema are categorized into biologics (monoclonal antibodies) and small molecule inhibitors.

## 3. WHAT TRADITIONAL IMMUNOSUPPRESSANTS ARE USED FOR ECZEMA?

Traditional immunosuppressive antimetabolites remain in frequent use despite being off-label in Canada in large part due to health system cost considerations.<sup>5,8,11</sup> Selection of these agents is based on individualized efficacy and safety considerations, while adhering to international management guidelines and requirements for screening and monitoring. Usage varies according to expertise, access to monitoring, as well as regional or national health system factors.

Cyclosporine is an effective small molecule calcineurin inhibitor that prevents IL-2 transcription resulting in reduced effector T cell function. Cyclosporine has long been approved by the European Medicines Agency (but not the FDA or Health Canada for refractory eczema).<sup>11,12</sup> It has been considered a first-line agent for adults with severe disease in European guidelines due its rapid onset; patients can achieve 51% and 72% improvement of eczema at week 2 and 12, respectively.<sup>13</sup> However, cyclosporine

should be administered in 3–6-month intervals for a maximum of 2 years to minimize side effects such as hypertension, nephrotoxicity and risk of malignancy or infection.<sup>11,14,15</sup> Unfortunately, relapse and rebound is common following cyclosporine discontinuation; therefore, careful tapering and/or switching to maintenance therapies is needed.<sup>11,14</sup>

Unlike cyclosporine, methotrexate works slowly, and patients often take as long as 8–12 weeks before responding optimally; however, methotrexate is generally considered a safer option for long-term maintenance.<sup>5,11,14</sup> This antifolate antimetabolite inhibits synthesis of DNA and RNA.<sup>16–19</sup> Up to 60% of patients can achieve improvement of disease whilst on methotrexate as part of a monotherapy or combination therapy regimen.<sup>20,21</sup> Methotrexate usage must be weighed against its teratogenic and hepatic adverse effects.<sup>11,14</sup> Mycophenolate mofetil and azathioprine are less commonly used systemic immunosuppressants for eczema patients but may be used as adjuncts or when cyclosporine and/or methotrexate are contraindicated.<sup>11,14,20,22</sup> While systemic glucocorticoids are a recognized rescue therapy for moderate-to-severe eczema, their usage is restricted to short-term management of acute flares due to their unfavorable safety profile with prolonged treatment.<sup>11,14</sup> Importantly, the cumulative risk of rescue corticosteroids must be considered across the lifespan.

#### 4. WHAT TARGETED AGENTS ARE USED, AND WHEN?

A rapid pace of translational discovery has led to landmark shifts in the management of eczema over the last six years: there are now four on-label therapies with demonstrated efficacy in AD and that are safe for long-term maintenance of remission (**Table 2**). Patients and providers are thus seeking improved health trajectories across the lifespan, with increasing awareness of ameliorated outcomes, due to the capacity for targeted agents to selectively modulate branches of the immune system without broad immunosuppression, or while minimizing off-target effects to other organs. Health systems are recognizing these novel agents and balancing econometric evaluations against budget impact analyses.

##### a. Targeted Biologics: Monoclonal Antibodies

Biologics for eczema are proliferating; notably, these selective agents are injections. As the first targeted agent approved for eczema, dupilumab is licensed for use across the greatest number of atopic conditions and has the widest age range of regulatory approvals (**Table 2**).<sup>23–25</sup> This fully humanized monoclonal antibody targets the alpha subunit of IL-4 receptor

(IL-4R)<sup>26</sup> blocking type 2 (IL-4 and IL-13) signaling, and significant skin clearance has been established in 3 pivotal trials for adults.<sup>27,28</sup> It has also been approved for children aged 6 to 11 years with uncontrolled eczema (**Tables 1 and 3**).<sup>29,30</sup> The FDA also accepted dupilumab for priority review for approval in children between the ages of 6 months and 5 years.<sup>31</sup> A phase 2/3 trial in this patient population found that 53% of such patients were able to achieve EASI75 at week 16 with dupilumab, versus 11% with placebo.<sup>32</sup> With a signal for conjunctivitis but otherwise minimal adverse effects, given its consistent safety profile for patients 6 years and older, dupilumab's strengths include efficacy over a range of other moderate-to-severe allergic diseases such as uncontrolled asthma and nasal polyps that may influence its selection in patients with these co-morbidities (**Table 1**).<sup>33</sup>

Talokinumab is another selective and high-affinity human monoclonal antibody against IL-13, the dominant Th2 cytokine in skin. It was approved by Health Canada for adults with moderate-to-severe eczema in late 2021;<sup>34,35</sup> public reimbursement in Canada is pending.<sup>31,32</sup> In clinical trials, the majority of talokinumab responders maintained their response through week 52 and there is some evidence for improved long-term response rates.<sup>34–36</sup> In pivotal trials, EASI75 at week 52 was maintained by 60% of treatment responders who continued talokinumab (vs. 33% who transitioned from talokinumab to placebo), after the week 16 primary endpoint in ECZTRA 1, and 56% who continued talokinumab (vs. 21% who transitioned to placebo) in ECZTRA 2. Talokinumab does not have any notable contraindications or additional safety monitoring requirements associated with its use for patients prior, during, or post initiation (**Table 3**).<sup>36</sup>

Of note, a recent Canadian literature review and expert clinical framework notes that exposure to dupilumab during pregnancy poses little risk to mother and fetus, with negligible absorption of dupilumab by infants who are breastfed by women taking dupilumab.<sup>33</sup>

##### b. Targeted Small Molecule Inhibitors: JAK1 Inhibitors (JAKi)

Biologic agents are appealing options for long-term maintenance due to their favorable safety profiles; however, their pharmacodynamics are slower than oral targeted agents. Patients suffering from moderate-to-severe eczema frequently require rapid rescue and remission of disease, as demonstrated by the prevalent use of systemic corticosteroids despite their broad adverse effect profiles. A new class of agents, the small molecule inhibitors of Janus kinases

(JAKi), control disease rapidly by interrupting signal transduction downstream of cytokine receptors;<sup>1</sup> JAKi are already used in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis (**Tables 1,2**).<sup>37,38</sup> The JAKi of interest for eczema in North America (upadacitinib and abrocitinib) are oral small molecule inhibitors with predominant selectivity for JAK1.<sup>5</sup> JAK1 inhibitors are highly effective at blocking signaling downstream of the type 2 cytokines that contribute to eczema pathophysiology; they also interrupt signaling downstream of other cytokine families, including interferons, the gp130 receptor group, IL-10-related, and common gamma chain cytokines.<sup>39,40</sup> While serious adverse effects of special interest have been highlighted in patients with rheumatoid arthritis under combination treatment with the less selective JAK inhibitor (JAK1/3) tofacitinib, leading to blanket inclusion of black box warnings for the JAK class across all diseases, this data has not been extrapolated to selective JAK1 inhibition in patients with eczema.<sup>41,42</sup> Notably, a wide range of topical and oral inhibitors of JAK and related kinases are under active development for a wide range of dermatologic conditions, including vitiligo and alopecia areata, which are common underlying comorbid conditions in patients with severe eczema.<sup>43</sup>

Upadacitinib was the first approved JAKi for moderate-to-severe eczema in adults and adolescents (>12 years).<sup>44,45</sup> In phase 3 studies, patients treated with upadacitinib achieve rapid control as early as week 4, with 70% EASI75 and IGA-AD scores by Week 16 compared to placebo (**Table 4**).<sup>46–48</sup> Notably, patients experienced rapid improvements in itch beginning as early as 1-2 days following the first dose. At higher dosing (30 mg) upadacitinib achieved higher skin clearance compared to dupilumab after four months, with 60.6% versus 38.7% achieving 90% improvement in the EASI.<sup>49</sup> Routine blood work is recommended pre-treatment with monitoring at 3 months and as per care required (**Table 3**).<sup>38</sup> Non-live vaccination prior to therapy, followed by booster vaccination after two months is recommended, with stronger recommendations in patients who are at a greater risk for developing shingles, including patients of Asian ethnicity. Shared decision-making is needed to review timing and options for therapy modifications during vaccinations.<sup>38</sup> Upadacitinib should be prescribed with caution in patients with infection, hematologic disorders, history of clotting, and liver or kidney impairment, and is contraindicated during pregnancy and breastfeeding.<sup>38</sup>

Abrocitinib is a comparable JAK1 inhibitor recently approved by Health Canada, with small differences in adverse effect profiles including a slightly lower signal

for acne.<sup>50,51</sup> Patients receiving abrocitinib also showed significantly greater improvements in their EASI75 and Investigator Global Assessment- Atopic Dermatitis (IGA-AD) scores compared with the placebo group across three pivotal registration studies (**Table 5**).<sup>26,50</sup> Unlike dupilumab and tralokinumab, upadacitinib and abrocitinib require additional safety considerations prior to and post initiation of therapy (**Table 3**).<sup>37</sup>

## 5. CHOOSING THE BEST SYSTEMIC ECZEMA THERAPY

The systemic therapy that best suits an individual's unique eczema presentation depends on multiple patient-specific factors, including age, underlying comorbidities, disease- and risk-factors, endotype variables and personal preferences, in addition to health system considerations related to reimbursement and access. However, only select therapeutic agents (cyclosporine, upadacitinib, abrocitinib, prednisone) have kinetics that are useful in achieving very rapid remission of eczema, while others (dupilumab, tralokinumab, methotrexate) have slower onset of action but also possess multiple years of data demonstrating durability of response over time with favorable safety profiles. In addition, restricted options are available for certain populations, including children and women of childbearing potential. For patients with health-related quality of life affected by comorbid atopic conditions like asthma and/or chronic rhinosinusitis with nasal polyps (CRSwNP), dupilumab remains advantageous (**Table 3**). Although tralokinumab may not be as efficacious as dupilumab at the time points considered here, it remains a viable alternative with fewer safety concerns than the JAK inhibitors and targets the key mediator in skin.<sup>10,52</sup> As more molecules progress through clinical development, including additional IL-13 inhibitors and biologics targeting OX40 or ligand co-stimulatory signaling, further research is required to determine how to personalize management approaches with the idealized aim to identify therapeutic approaches that may alter the natural history of disease.

The author wishes to acknowledge the contribution of Radia Kamal, Aashna Jain, and Valerie Jack for their help in the research and writing of this manuscript

| MOA                               | Rx                        | Children                     |        |            |                        |         |          | Adolescent and Adult       |         |         |          |            |     |
|-----------------------------------|---------------------------|------------------------------|--------|------------|------------------------|---------|----------|----------------------------|---------|---------|----------|------------|-----|
|                                   |                           | Children<br>6 months-5 years |        |            | Children<br>6-11 years |         |          | Adolescents<br>12-17 years |         |         | Adults   |            |     |
|                                   |                           | AD                           | Asthma | CRS<br>wNP | EoE                    | AD      | Asthma   | CRS<br>wNP                 | EoE     | Eczema  | Asthma   | CRS<br>wNP | EoE |
| Anti-IL-4R<br>alpha<br>(IL4/IL13) | Dupilumab <sup>1</sup>    | Pending*                     |        |            |                        | ✓!<br>@ | ✓!<br>@# |                            | Pending | ✓!<br>@ | ✓!<br>@# | ✓!<br>@#   | @   |
| Anti-IL-13                        | Tralokinumab <sup>2</sup> |                              |        |            |                        |         |          |                            |         | ✓!<br>@ |          |            |     |
| Anti-JAK1                         | Upadacitinib <sup>3</sup> |                              |        |            |                        | ✓!<br>@ |          |                            |         | ✓!<br>@ |          |            | ✓** |
| Anti-JAK1                         | Abrocitinib <sup>4</sup>  |                              |        |            |                        |         |          |                            |         | ✓!      |          |            |     |

Table 1. New systemic therapies approved for patients with Atopic Dermatitis (Eczema), considering other atopic disorders, as of April 2022.

CRSwNP (chronic rhinosinusitis with nasal polyposis)

! Approved by Health Canada as of April 2022

@ Approved by U.S. FDA

# Approved as add-on maintenance treatment only

\* Accepted for Priority Review by the U.S. FDA5

\*\* Approved for moderate-to-severe ulcerative colitis, active psoriatic arthritis, and moderately to severely active rheumatoid arthritis



| Mechanism of Action         | Therapeutic Name | Phase 2                       | Phase 3                        | FDA Approval | Health Canada Approval | Phase 4                       |
|-----------------------------|------------------|-------------------------------|--------------------------------|--------------|------------------------|-------------------------------|
| Anti-IL-4R alpha (IL4/IL13) | Dupilumab        | ✓ <sup>1</sup> <sup>!@#</sup> | ✓ <sup>2</sup> <sup>!@#</sup>  | ✓            | ✓                      | ✓ <sup>3</sup> <sup>!@#</sup> |
|                             | Tralokinumab     | ✓ <sup>4</sup> <sup>!</sup>   | ✓ <sup>5</sup> <sup>!@</sup>   | ✓            | ✓                      |                               |
| Anti-IL-13                  | Lebrikizumab     | ✓ <sup>6</sup> <sup>!</sup>   | ✓ <sup>7</sup> <sup>!@</sup>   |              |                        |                               |
|                             | Nemolizumab      | ✓ <sup>8</sup> <sup>!@</sup>  | ✓ <sup>9</sup> <sup>!@</sup>   |              |                        |                               |
| Anti-IL-31                  | Upadacitinib     | ✓ <sup>10</sup> <sup>!</sup>  | ✓ <sup>11</sup> <sup>!@</sup>  | ✓            | ✓                      |                               |
|                             | Abrocitinib      | ✓ <sup>12</sup> <sup>!</sup>  | ✓ <sup>13</sup> <sup>!@</sup>  | ✓            |                        |                               |
| Non-Specific Anti-JAK1/2    | Baricitinib      | ✓ <sup>14</sup> <sup>!</sup>  | ✓ <sup>15</sup> <sup>!@#</sup> |              |                        |                               |

Table 2. New and emerging therapies in clinical development for the treatment of Atopic Dermatitis (Eczema) as of April 2022.<sup>5</sup>

**Green** (Approved for use); **Orange** (Clinical development ongoing - Not approved); **Yellow** (Not filing for approval in North America)

Disease Severity: M (moderate); MS (moderate-to-severe); S (severe)

Study Population: ! (Adult); @ (Adolescent); # (Children)

Study status "Completed" unless labelled with any of the following: \$ (Active, not recruiting); ^ (Active, recruiting); \* (Terminated)

<sup>1</sup> Dupilumab Phase 2 Clinical Trials: NCT024027756<sup>@#MS</sup>, NCT01859988<sup>MS</sup>, NCT02210780<sup>MS</sup>, NCT01639040<sup>MS</sup>, NCT01979016<sup>MS</sup>, NCT01548404<sup>MS</sup>, NCT03346434<sup>#MS</sup>

<sup>2</sup> Dupilumab Phase 3 Clinical Trials: NCT03346434<sup>MS</sup>, NCT01949311<sup>MS</sup>, NCT02277769<sup>MS</sup>, NCT03912259<sup>MS</sup>, NCT02277743<sup>MS</sup>, NCT02260986<sup>MS</sup>, NCT02755649<sup>MS</sup>, NCT02395133<sup>MS</sup>, NCT03054428<sup>@MS</sup>, NCT04678882<sup>@#MS</sup>, NCT03345914<sup>#MS</sup>

<sup>3</sup> Dupilumab Phase 4 Clinical Trials: NCT03293030<sup>MS</sup>, NCT03667014<sup>MS</sup>, NCT03389893<sup>MS</sup>, NCT04358224<sup>MS</sup>, NCT04447417<sup>@MS</sup>, NCT05203380<sup>@MS</sup>, NCT04823130<sup>MS</sup>, NCT04033336<sup>MS</sup>, NCT04718870<sup>#MS</sup>, NCT05265234<sup>MS</sup>

<sup>4</sup> Tralokinumab Phase 2 Clinical Trials: NCT04556446<sup>MS</sup>, NCT02347176<sup>MS</sup>

<sup>5</sup> Tralokinumab Phase 3 Clinical Trials: NCT05194540<sup>MS</sup>, NCT03587805<sup>@MS</sup>, NCT03761537<sup>MS</sup>, NCT04587453<sup>MS</sup>, NCT03363854<sup>MS</sup>, NCT03526861<sup>@MS</sup>, NCT03160885<sup>MS</sup>, NCT03131648<sup>MS</sup>

<sup>6</sup> Lebrikizumab Phase 2 Clinical Trials: NCT02465606<sup>MS</sup>, NCT03443024<sup>MS</sup>, NCT02340234<sup>MS</sup>

<sup>7</sup> Lebrikizumab Phase 3 Clinical Trials: NCT04250350<sup>@MS</sup>, NCT04178967<sup>@MS</sup>, NCT04146363<sup>\$@MS</sup>, NCT04250337<sup>@MS</sup>, NCT04626297<sup>MS</sup>, NCT04392154<sup>MS</sup>, NCT05149313<sup>MS</sup>, NCT04760314<sup>\$@MS</sup>

<sup>8</sup> Nemolizumab Phase 2 Clinical Trials: NCT04921345<sup>MS</sup>, NCT03921411<sup>@MS</sup>, NCT01986933<sup>MS</sup>, NCT03100344<sup>MS</sup>, NCT04365387<sup>MS</sup>

<sup>9</sup> Nemolizumab Phase 3 Clinical Trials: NCT03985943<sup>@MS</sup>, NCT03989349<sup>@MS</sup>, NCT03989206<sup>MS</sup>

<sup>10</sup> Upadacitinib Phase 2 Clinical Trials: NCT02925117<sup>MS</sup>

<sup>11</sup> Upadacitinib Phase 3 Clinical Trials: NCT03738397<sup>MS</sup>, NCT04195698<sup>MS</sup>, NCT03569293<sup>@MS</sup>, NCT03568318<sup>\$@MS</sup>, NCT03607422<sup>\$@MS</sup>, NCT03661138<sup>\$@MS</sup>

<sup>12</sup> Abrocitinib Phase 2 Clinical Trials: NCT03915496<sup>MS</sup>, NCT02780167<sup>MS</sup>

<sup>13</sup> Abrocitinib Phase 3 Clinical Trials: NCT04345367<sup>MS</sup>, NCT03720470<sup>MS</sup>, NCT03796676<sup>@MS</sup>, NCT03575871<sup>@MS</sup>, NCT03349060<sup>@MS</sup>, NCT03422822<sup>\$@MS</sup>

<sup>14</sup> Baricitinib Phase 2 Clinical Trials: NCT02576938<sup>MS</sup>

<sup>15</sup> Baricitinib Phase 3 Clinical Trials: NCT03952559<sup>@MS</sup>, NCT03559270<sup>\$MS</sup>, NCT03435081<sup>MS</sup>, NCT03334422<sup>MS</sup>, NCT03334435<sup>MS</sup>, NCT03733301<sup>MS</sup>, NCT03428100<sup>\$MS</sup>, NCT03334396<sup>MS</sup>

|                                                                         | Dupilumab (Dupixent®) <sup>1</sup>                                                                                                                              | Talokinumab (Adtralza®) <sup>2</sup>                                                                                                                                                                                                                                                                                                       | Upadacitinib (Rinvoq®) <sup>3</sup>                                                                                                                                                            | Abrocitinib (Cibinqo®) <sup>4</sup>                                                                                                                                                                                                                                                             |
|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Patient Population per Health Canada                                    | 6 years and older                                                                                                                                               | 18 years and older                                                                                                                                                                                                                                                                                                                         | 12 years and older                                                                                                                                                                             | 18 years and older                                                                                                                                                                                                                                                                              |
| Indications                                                             | Moderate-to-severe AD, asthma, severe chronic rhinosinusitis with nasal polypsis                                                                                | Moderate-to-severe AD                                                                                                                                                                                                                                                                                                                      | Moderate-to-severe AD, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis                                                                                                           | Moderate-to-severe AD                                                                                                                                                                                                                                                                           |
| Contraindications                                                       | Hypersensitivity to dupilumab                                                                                                                                   | Hypersensitivity to talokinumab                                                                                                                                                                                                                                                                                                            | Hypersensitivity to upadacitinib                                                                                                                                                               | Antiplatelet therapies except for low-dose aspirin during the first 3 months of treatment                                                                                                                                                                                                       |
| Relative Contraindications and/or Black Box Warnings                    | Pregnancy                                                                                                                                                       | Pregnancy                                                                                                                                                                                                                                                                                                                                  | Pregnancy; Breastfeeding; Active serious infection, hematologic disorders, severe renal and/or hepatic impairment, malignancy, thrombosis                                                      | Pregnancy; Breastfeeding; Active serious infection, hematologic disorders, severe renal and/or hepatic impairment, malignancy, thrombosis, major adverse cardiovascular events                                                                                                                  |
| Route of Administration                                                 | Subcutaneous Injection                                                                                                                                          | Subcutaneous Injection                                                                                                                                                                                                                                                                                                                     | Oral                                                                                                                                                                                           | Oral                                                                                                                                                                                                                                                                                            |
| Mode of Action                                                          | Anti-IL-4R alpha (IL4/IL13)                                                                                                                                     | Anti-IL-13                                                                                                                                                                                                                                                                                                                                 | JAK1 Inhibitor                                                                                                                                                                                 | JAK1 Inhibitor                                                                                                                                                                                                                                                                                  |
| Adverse Events (based on product monograph, >1%)                        | a) Injection site reactions (9.7% dupilumab, 5.5% placebo)<br>b) Conjunctivitis (9.7% dupilumab, 3.2% placebo)<br>c) Oral herpes (3.6% dupilumab, 1.6% placebo) | a) Upper respiratory tract infections (ECZTRA 1/2: 23.8% 300 mg, 20.2% placebo; ECZTRA 3: 29.0% 300 mg, 15.1% placebo)<br>b) Injection site reactions (ECZTRA 1 & 2: 7.3% 300 mg, 4.0% placebo; ECZTRA 3: 10.7% 300 mg, 0.8% placebo)<br>c) Conjunctivitis (ECZTRA 1 & 2: 5.1% 300 mg, 1.8% placebo; ECZTRA 3: 11.1% 300 mg, 3.2% placebo) | a) Upper respiratory tract infection (25.4% 30 mg, 22.6% 15 mg, 16.5% placebo)<br>b) Acne (15.1% 30 mg, 9.6% 15 mg, 2.2% placebo)<br>c) Herpes simplex (8.4% 30 mg, 4.1% 15 mg, 1.7% placebo)  | a) Nasopharyngitis (8.7% 200 mg, 12.4% 100 mg, 7.9% placebo)<br>b) Nausea (14.5% 200 mg, 6.0% 100 mg, 2.1% placebo)<br>c) Headache (7.8% 200 mg, 6.0% 100 mg, 3.5% placebo)<br>d) Herpes simplex (4.2% 200 mg, 3.3% 100 mg, 1.8% placebo)                                                       |
| Serious Adverse Events of Special Interest (based on product monograph) | N/A                                                                                                                                                             | N/A                                                                                                                                                                                                                                                                                                                                        | Malignancy (0 patient on placebo, 2 on 15 mg, 7 on 30 mg)<br>Serious Infections (5 patients on placebo, 26 on 15 mg, 30 on 30 mg)<br>Thrombosis (2 patient on placebo, 1 on 15 mg, 1 on 30 mg) | Malignancy (0 patients on placebo, 4 on 100 mg, 2 on 200 mg)<br>Serious Infections (2 patients on placebo, 18 on 100 mg, 16 on 200 mg)<br>Thrombosis (0 patients on placebo, 0 on 100 mg, 5 on 200 mg)<br>Major Adverse Cardiovascular Events (0 patients on placebo, 1 on 100 mg, 2 on 200 mg) |
| Recommended screening and monitoring Blood Work                         | N/A                                                                                                                                                             | N/A                                                                                                                                                                                                                                                                                                                                        | Screening: HepB, HepC, TB, LFT, CBC, lipid panel<br>Monitoring: CBC, LFT, lipid panel                                                                                                          | Screening: HepB, HepC, TB, LFT, CBC, lipid panel<br>Monitoring: CBC, LFT, lipid panel                                                                                                                                                                                                           |

Table 3. Comparison of targeted systemics approved in Canada for moderate-to-severe atopic dermatitis (AD) as of April 2022.

|                                         | MEASURE Up 1 <sup>6</sup>       |                                        |                                 | Measure Up 2 <sup>7</sup>               |                                 | AD Up <sup>8</sup>              |                                        | HEADS UP <sup>9</sup>           |
|-----------------------------------------|---------------------------------|----------------------------------------|---------------------------------|-----------------------------------------|---------------------------------|---------------------------------|----------------------------------------|---------------------------------|
|                                         | % of patients to achieve EASI75 | % of patients to achieve IGA of 0 or 1 | % of patients to achieve EASI75 | % of patients to achieve vIGA of 0 or 1 | % of patients to achieve EASI75 | % of patients to achieve EASI75 | % of patients to achieve IGA of 0 or 1 |                                 |
| Treatment (upadacitinib versus placebo) |                                 |                                        |                                 |                                         |                                 |                                 |                                        |                                 |
| 15 mg                                   | 70%                             | 48%                                    | 60%                             | 39%                                     | 65%                             | 40%                             |                                        | % of patients to achieve EASI75 |
| 30 mg                                   | 80%                             | 62%                                    | 73%                             | 52%                                     | 77%                             | 59%                             |                                        | 71%                             |
| Placebo                                 | 16%                             | 8%                                     | 13%                             | 5%                                      | 26%                             | 11%                             |                                        |                                 |
| Dupilumab 300 mg                        |                                 |                                        |                                 |                                         |                                 |                                 |                                        | 61%                             |

Table 4: Summary of primary endpoint results from the Measure Up 1 and 2, AD Up, and HEADS UP upadacitinib Atopic Dermatitis trials. EASI75 (at least 75% improvement from baseline in Eczema Area and Severity Index)  
IGA (Investigator Global Assessment)

|                                        | JADE MONO-1                     |                                                            | JADE MONO-2                     |                                                            | JADE COMPARE                    |                                                            |
|----------------------------------------|---------------------------------|------------------------------------------------------------|---------------------------------|------------------------------------------------------------|---------------------------------|------------------------------------------------------------|
|                                        | % of patients to achieve EASI75 | % of patients to achieve IGA of 0 or 1 & 2-point reduction | % of patients to achieve EASI75 | % of patients to achieve IGA of 0 or 1 & 2-point reduction | % of patients to achieve EASI75 | % of patients to achieve IGA of 0 or 1 & 2-point reduction |
| Treatment (abrocitinib versus placebo) |                                 |                                                            |                                 |                                                            |                                 |                                                            |
| 100 mg                                 | 40%                             | 24%                                                        | 44%                             | 28%                                                        | 58%                             | 36%                                                        |
| 200 mg                                 | 62%                             | 44%                                                        | 61%                             | 38%                                                        | 70%                             | 48%                                                        |
| Placebo                                | 12%                             | 8%                                                         | 10%                             | 9%                                                         | 27%                             | 14%                                                        |
| Dupilumab 300 mg                       |                                 |                                                            |                                 |                                                            | 58%                             | 36%                                                        |

Table 5: Summary of primary endpoint results from the JADE MONO-1, JADE MONO-2, and JADE COMPARE abrocitinib atopic dermatitis trials.<sup>10</sup> EASI75 (at least 75% improvement from baseline in Eczema Area and Severity Index)  
IGA (Investigator Global Assessment)



## References (Supplemental Tables)

1. Dupixent® (dupilumab injection) Canada Product Monograph. hres.ca. Updated November 12, 2020. Accessed April 8, 2022. [https://pdf.hres.ca/dpd\\_pm/00058817.PDF](https://pdf.hres.ca/dpd_pm/00058817.PDF)
2. LEO Pharma Inc. Adtralza® (tralokinumab) Canada Product Monograph. leo-pharma.ca. Accessed April 14, 2022. <https://www.leo-pharma.ca/Files/Billeder/Adtralza%20PM%20-%2013%20OCT%202021.pdf>
3. AbbVie Corporation. Rinvoq® (upadacitinib) Canada Product Monograph. abbvie.ca. Updated January 27, 2022. Accessed April 11, 2022. [https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/RINVOQ\\_PM\\_EN.pdf#:~:text=PRODUCT%20MONOGRAPH%20INCLUDING%20PATIENT%20MEDICATION%20INFORMATION%20PrRINVOQ%C2%AE%20Upadacitinib,Extended-release%20tablets%2C%2030%20mg%20upadacitinib%2C%20oral%20Selective%20immunosuppressant](https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/RINVOQ_PM_EN.pdf#:~:text=PRODUCT%20MONOGRAPH%20INCLUDING%20PATIENT%20MEDICATION%20INFORMATION%20PrRINVOQ%C2%AE%20Upadacitinib,Extended-release%20tablets%2C%2030%20mg%20upadacitinib%2C%20oral%20Selective%20immunosuppressant)
4. CINBQOTM (abrocitinib) U.S. Product Monograph. pfizer.com. Updated January 2022. Accessed April 11, 2022. [https://cdn.pfizer.com/pfizercom/USPI\\_Med\\_Guide\\_CIBINQO\\_Abrocitinib\\_tablet.pdf](https://cdn.pfizer.com/pfizercom/USPI_Med_Guide_CIBINQO_Abrocitinib_tablet.pdf)
5. Home - ClinicalTrials.gov. Accessed April 14, 2022. <https://clinicaltrials.gov/ct2/home>
6. Improvements in Skin Clearance, Itch Observed With Upadacitinib in Atopic Dermatitis Study. Accessed April 14, 2022. <https://www.empr.com/home/news/drugs-in-the-pipeline/upadacitinib-severe-atopic-dermatitis-improvement-in-skin-care/>
7. Second Trial Evaluating Upadacitinib in Atopic Dermatitis Meets End Point. Accessed April 14, 2022. <https://www.empr.com/home/news/drugs-in-the-pipeline/moderate-to-severe-atopic-dermatitis-upadacitinib-rinvoq-abbvie/>
8. Rinvoq Gains FDA Approval for Atopic Dermatitis - Dermatology Advisor. Accessed April 14, 2022. <https://www.dermatologyadvisor.com/home/topics/dermatitis/rinvoq-gains-fda-approval-for-atopic-dermatitis/>
9. RINVOQTM (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis | AbbVie News Center. Accessed April 14, 2022. <https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-achieved-superiority-versus-dupixent-dupilumab-for-primary-and-all-ranked-secondary-endpoints-in-phase-3b-head-to-head-study-in-adults-with-atopic-dermatitis.htm>
10. U.S. FDA Approves Pfizer's CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis | Pfizer. Accessed April 14, 2022. <https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults>

## References (Main Article):

1. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. *Nature Reviews Drug Discovery*. 2022;21(1):21-40. doi:10.1038/s41573-021-00266-6
2. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. *J Invest Dermatol*. 2014;134(6):1527-1534. doi:10.1038/JID.2013.446
3. Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatology*. 2020;156(8):863-873. doi:10.1001/jamadermatol.2020.1406
4. Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. *Dermatitis*. 2014;25(3):107-114. doi:10.1097/DER.0000000000000034
5. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. *Lancet*. 2020;396(10247):345-360. doi:10.1016/S0140-6736(20)31286-1
6. Bieber T, Traidl-Hoffmann C, Schäppi G, Lauener R, Akdis C, Schmid-Grendlmeier P. Unraveling the complexity of atopic dermatitis: The CK-CARE approach toward precision medicine. *Allergy*. 2020;75(11):2936-2938. doi:10.1111/ALL.14194
7. Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. *Allergy*. 2018;73(6):1284-1293. doi:10.1111/ALL.13401
8. Ghazal S, Ridha Z, D'Aguanno K, et al. Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II. *Frontiers in Medicine*. 2022;9. doi:10.3389/fmed.2022.821871
9. Maintz L, Bieber T, Bissonnette R, Jack C. Measuring Atopic Dermatitis Disease Severity: The Potential for Electronic Tools to Benefit Clinical Care. *J Allergy Clin Immunol Pract*. 2021;9(4):1473-1486.e2. doi:10.1016/J.JAIP.2021.02.027
10. Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis. *JAMA Dermatology*. Published online March 16, 2022. doi:10.1001/jamadermatol.2022.0455
11. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *Journal of the European Academy of Dermatology and Venereology*. 2018;32(6):850-878. doi:10.1111/jdv.14888
12. Wolverton SE, Wu JJ. Comprehensive Dermatologic Drug Therapy.
13. Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. *Journal of Allergy and Clinical Immunology*. 2014;133(6):1626-1634. doi:10.1016/J.JACI.2014.03.003
14. Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. *Clin Rev Allergy Immunol*. 2021;61(3):324-338. doi:10.1007/S12016-021-08880-3
15. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol*. 2007;21(5):606-619. doi:10.1111/J.1468-3083.2006.02023.X
16. Chen MJ, Shimada T, Moulton AD, et al. The functional human dihydrofolate reductase gene. *The Journal of Biological Chemistry*. 1984;259(6):3933-3943. doi:10.1016/S0021-9258(17)43186-3
17. Chen MJ, Shimada T, Moulton AD, Harrison M, Nienhuis AW. Intronless human dihydrofolate reductase genes are derived from processed RNA molecules. *Proc Natl Acad Sci U S A*. 1982;79(23):7435-7439. doi:10.1073/pnas.79.23.7435
18. Benham CJ, Mielke SP. DNA mechanics. *Annual Review of Biomedical Engineering*. 2005;7:21-53. doi:10.1146/annurev.bioeng.6.062403.132016
19. Burghardt B, Hartmann AK. RNA secondary structure design. *Physical Review E*. 2007;75(2):021920. doi:10.1103/PhysRevE.75.021920
20. Lee JH, Yun SJ, Lee JB, Lee SC. Therapeutic Efficacy and Safety of Methotrexate in Moderate-to-Severe Atopic Dermatitis: A Retrospective Study of Korean Patients at Tertiary Referral Hospital. *Ann Dermatol*. 2020;32(5):402-408. doi:10.5021/AD.2020.32.5.402
21. Goujon C, Viguier M, Staumont-Sallé D, et al. Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial. *J Allergy Clin Immunol Pract*. 2018;6(2):562-569.e3. doi:10.1016/J.JAIP.2017.07.007
22. Sahni VN, Balogh EA, Strowd LC, Feldman SR. The evolving atopic dermatitis management landscape. *Expert Opin Pharmacother*. 2022;23(4):517-526. doi:10.1080/14656566.2021.1999412
23. Shirley M. Dupilumab: First Global Approval. *Drugs*. 2017;77(10):1115-1121. doi:10.1007/S40265-017-0768-3
24. DUPIXENT® (dupilumab injection) now approved by Health Canada for patients with severe asthma - Nov 17, 2020. Accessed April 14, 2022. <http://sanoficanada.mediaroom.com/2020-11-17-DUPIXENT-R-dupilumab-injection-now-approved-by-Health-Canada-for-patients-with-severe-asthma>

25. Sanofi-aventis Canada Inc. Dupixent® (dupilumab injection) Canada Product Monograph. hres.ca. Published November 30, 2017. Updated November 12, 2020. Accessed April 8, 2022. [https://pdf.hres.ca/dpd\\_pm/00058817.PDF](https://pdf.hres.ca/dpd_pm/00058817.PDF)
26. Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. *N Engl J Med*. 2021;384(12):1101-1112. doi:10.1056/NEJMOA2019380
27. Worm M, Simpson EL, Thaçi D, et al. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatol*. 2020;156(2):131-143. doi:10.1001/JAMADERMATOL.2019.3617
28. Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. *Allergy*. 2021;76(4):1053-1076. doi:10.1111/ALL.14631
29. Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years - Feb 23, 2021. Accessed April 14, 2022. <http://sanoficanada.mediaroom.com/2021-02-23-Health-Canada-approves-DUPIXENT-R-dupilumab-injection-as-the-first-biologic-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-children-aged-6-to-11-years>
30. Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis - Sanofi. Accessed April 14, 2022. <https://www.sanofi.com/en/media-room/press-releases/2020/2020-05-26-17-40-00>
31. FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis - Sanofi. Accessed April 14, 2022. <https://www.sanofi.com/en/media-room/press-releases/2022/2022-02-10-07-00-00-2382407>
32. Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session | Regeneron Pharmaceuticals Inc. Accessed April 14, 2022. <https://investor.regeneron.com/news-releases/news-release-details/positive-phase-3-dupixent-dupilumab-data-children-6-months-5>
33. Papp KA, Hong C ho, Lansang MP, et al. Practical Management of Patients with Atopic Dermatitis on Dupilumab. *Dermatol Ther (Heidelb)*. 2021;11(5):1805-1828. doi:10.1007/S13555-021-00586-W
34. LEO Pharma Inc. Adtralza® (tralokinumab) Canada Product Monograph. leo-pharma.ca. Published October 13, 2021. Accessed April 13, 2022. <https://www.leo-pharma.ca/Files/Billeder/Adtralza%20PM%20-%2013%20OCT%202021.pdf>
35. Health Canada approves ADTRALZA® (tralokinumab) as a treatment for adults with moderate-to-severe atopic dermatitis | LEO Pharma. Accessed April 14, 2022. <https://www.leo-pharma.ca/Default.aspx?ID=31612>
36. Breaking News: FDA Approves Adbry™ (Tralokinumab-ldrm) | National Eczema Association. Accessed April 14, 2022. <https://nationaleczema.org/breaking-news-fda-approves-adbry-tralokinumab-ldrm/>
37. CINBQOTM (abrocitinib) U.S. Product Monograph. pfizer.com. Updated January 2022. Accessed April 11, 2022. [https://cdn.pfizer.com/pfizercom/USPI\\_Med\\_Guide\\_CIBINQO\\_Abrocitinib\\_tablet.pdf](https://cdn.pfizer.com/pfizercom/USPI_Med_Guide_CIBINQO_Abrocitinib_tablet.pdf)
38. AbbVie Corporation. Rinvoq® (upadacitinib) Canada Product Monograph. abbvie.ca. Published December 23, 2019. Updated January 27, 2022. Accessed April 11, 2022. [https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/RINVOQ\\_PM\\_EN.pdf#:~:text=PRODUCT%20MONOGRAPH%20INCLUDING%20PATIENT%20MEDICATION%20INFORMATION%20PrRINVOQ%C2%AE%20Upadacitinib,Extended-release%20tablets%2C%2030%20mg%20upadacitinib%2C%20oral%20Selective%20immunosuppressant](https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/RINVOQ_PM_EN.pdf#:~:text=PRODUCT%20MONOGRAPH%20INCLUDING%20PATIENT%20MEDICATION%20INFORMATION%20PrRINVOQ%C2%AE%20Upadacitinib,Extended-release%20tablets%2C%2030%20mg%20upadacitinib%2C%20oral%20Selective%20immunosuppressant)
39. Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. *Signal Transduction and Targeted Therapy*. 2021;6(1). doi:10.1038/S41392-021-00791-1
40. Ge T, Jhala G, Fynch S, et al. The JAK1 Selective Inhibitor ABT 317 Blocks Signaling Through Interferon-γ and Common γ Chain Cytokine Receptors to Reverse Autoimmune Diabetes in NOD Mice. *Front Immunol*. 2020;11. doi:10.3389/FIMMU.2020.588543
41. Machado MA de Á, Moura CS de, Guerra SF, Curtis JR, Abrahamowicz M, Bernatsky S. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. *Arthritis Res Ther*. 2018;20(1). doi:10.1186/S13075-018-1539-6
42. Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. *Drugs*. 2017;77(18):1987-2001. doi:10.1007/S40265-017-0835-9
43. Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. *J Am Acad Dermatol*. 2017;76(4):736. doi:10.1016/J.JAAD.2016.12.005
44. Breaking News: FDA Approves Rinvoq® (Upadacitinib) | National Eczema Association. Accessed April 14, 2022. <https://nationaleczema.org/rinvoq-approval/>
45. European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis | AbbVie News Center. Accessed April 14, 2022. <https://news.abbvie.com/news/press-releases/european-commission-approves-rinvoq-upadacitinib-as-first-jak-inhibitor-in-european-union-for-treatment-both-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis.htm>
46. Rinvoq Gains FDA Approval for Atopic Dermatitis - Dermatology Advisor. Accessed April 14, 2022. <https://www.dermatologyadvisor.com/home/topics/dermatitis/rinvoq-gains-fda-approval-for-atopic-dermatitis/>
47. Improvements in Skin Clearance, Itch Observed With Upadacitinib in Atopic Dermatitis Study. Accessed April 14, 2022. <https://www.empr.com/home/news/drugs-in-the-pipeline/upadacitinib-severe-atopic-dermatitis-improvement-in-skin-care/>
48. Second Trial Evaluating Upadacitinib in Atopic Dermatitis Meets End Point. Accessed April 14, 2022. <https://www.empr.com/home/news/drugs-in-the-pipeline/moderate-to-severe-atopic-dermatitis-upadacitinib-rinvoq-abbvie/>
49. Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatology*. 2021;157(9):1047-1055. doi:10.1001/JAMADERMATOL.2021.3023
50. <https://www.pfizer.ca/health-canada-approves-use-cibinqo-abrocitinib-treatment-patients-12-moderate-severe-atopic>
51. Deeks ED, Duggan S. Abrocitinib: First Approval. *Drugs*. 2021;81(18):2149-2157. doi:10.1007/S40265-021-01638-3
52. ICER Publishes Evidence Report on Therapies for Atopic Dermatitis - ICER. Accessed April 14, 2022. <https://icer.org/news-insights/press-releases/icer-publishes-evidence-report-on-therapies-for-atopic-dermatitis/>
53. De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, Hercogová J, Hong CH, Katoh N, Pink AE, Richard MA, Shumack S, Silvestre JF, Weidinger S. Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. *Acta Derm Venereol*. 2021 Feb 17;101(2):adv00402. doi: 10.2340/00015555-3751. PMID: 33491094; PMCID: PMC9366686.